Method of predicting responsiveness of wet amd patient to anti-vegf therapy
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsKeiichi Shibagaki, Masanao Toshimori, Koji Oka, Shingo Maeda, Hiroshi Inoue
Life of this patent
Estimating the term…
Loading patent…
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsKeiichi Shibagaki, Masanao Toshimori, Koji Oka, Shingo Maeda, Hiroshi Inoue
Estimating the term…
The disclosure provides a method of predicting the responsiveness of a wet AMD patient to anti-VEGF therapy comprising (1) determining the level of at least one marker protein selected from the group consisting of TGF-beta, BMP9, angiopoietin-1, and angiopoietin-2 in a blood, plasma or serum sample obtained from the patient, and (2) predicting the responsiveness of the patient to the anti-VEGF therapy with reference to the level determined in step (1), as well as a diagnostic agent for use in the method.
A method of predicting the responsiveness of a wet AMD patient to anti-VEGF therapy, comprising:
A diagnostic agent for predicting the responsiveness of a wet AMD patient to anti-VEGF therapy, comprising at least one antibody selected from the group consisting of anti-TGF-beta antibody, anti-BMP9 antibody, anti-angiopoietin-1 antibody, and anti-angiopoietin-2 antibody.
Dependencies are inferred from the claim text.